A practical reference on RP-HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
== Classification == Metal complexes, also including all coordination compounds, include virtually all metal compounds. The study of "coordination chemistry" is the study of "inorganic chemistry" of all alkali and alkaline earth metals, transition metals, lanthanides, actinides, and metalloids. Thus, coordination chemistry is the chemistry of the majority of the periodic table. Metals and metal ions exist, in the condensed phases at least, only surrounded by ligands. The areas of coordination chemistry can be classified according to the nature of the ligands, in broad terms:
Uroguanylin is a 16 amino acid peptide that is secreted by enterochromaffin cells in the duodenum and proximal small intestine. Guanylin acts as an agonist of the guanylyl cyclase receptor guanylate cyclase 2C (GC-C), and regulates electrolyte and water transport in intestinal and renal epithelia. By agonizing this guanylyl cyclase receptor, uroguanylin and guanylin cause intestinal secretion of chloride and bicarbonate to dramatically increase; this process is helped by the second messenger cGMP. Its sequence is H-Asn-Asp-Asp-Cys(1)-Glu-Leu-Cys(2)-Val-Asn-Val-Ala-Cys(1)-Thr-Gly-Cys(2)-Leu-OH. In humans, the uroguanylin peptide is encoded by the GUCA2B gene. Uroguanylin may be involved in appetite and perceptions of 'fullness' after eating meals, as suggested by a study into mice.
Since 1921, the Toronto Transit Commission (TTC) gradually expanded its public transportation network to Scarborough. Today, it operates bus and rapid transit routes in the district. Line 2 Bloor–Danforth has three subway stations in Scarborough: Victoria Park, Warden, and Kennedy, the current eastern terminus. In 1985, the Government of Ontario opened the Scarborough RT, an above-ground light metro line that operated between Kennedy station at its west and McCowan Road at its east. In 2023, the line shut down permanently due to aging Infrastructure which also caused a derailment earlier that year. Construction of an extension of Line 2 further east into Scarborough started in June 2021 and is expected to be complete around 2030. The line will be extended 7.8 kilometres from Kennedy station with stations at McCowan Road-Lawrence Avenue, Scarborough Centre, and McCowan Road-Sheppard Avenue. Opened in February 2026, Line 5 Eglinton is a light rail line with its eastern terminus at Kennedy station. The City of Toronto is also proposing another light rail line known as the Eglinton East LRT that is planned to operate from Kennedy station to the University of Toronto Scarborough. Seven rail stations also provide access to two commuter rail lines operated by GO Transit. The Lakeshore East line runs across the south end of the district with Rouge Hill GO Station, Guildwood GO Station, Eglinton GO Station, and Scarborough GO Station running from east to west.
== External links == "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Hommes et femmes" [Men and women]. Observatoire des Inégalités (in French). Archived from the original on February 19, 2007. "Lutte contre les discriminations et promotion de l'égalité" [Fighting discrimination and promoting equality]. Defenseurs des droits (in French). Archived from the original on June 13, 2017. "La discrimination des femmes : un sujet d'actualité" [Discrimination against women: a topical issue]. CentrOjeunes (in French). December 6, 2012. Archived from the original on August 8, 2016. "Discrimination des femmes à l'embauche" [Discrimination against women in hiring] (in French). Archived from the original on March 28, 2007. "Haut conseil à l'égalité des droits" [High Council for Equal Rights]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on May 22, 2013. "Secrétariat d'état chargé de l'égalité entre femmes et hommes et de la lutte contre les discriminations" [State Secretariat for Gender Equality and Anti-Discrimination]. Haut Conseil a L'égalité entre les femmes et les hommes (in French). Archived from the original on January 7, 2013. "Maison de la justice et du droit" [House of Justice and Law] (in French). Archived from the original on April 12, 2013. "Association européenne contre les Violences faites aux Femmes au Travail" [European Association Against Violence Against Women at Work] (in French).
Sources: en.wikipedia.org
=== Blood for Britain === The Blood for Britain program during the early 1940s was quite successful (and popular in the United States) based on Charles Drew's contribution. A large project began in August 1940 to collect blood in New York City hospitals for the export of plasma to Britain. Drew was appointed medical supervisor of the "Plasma for Britain" project. His notable contribution at this time was to transform the test tube methods of many blood researchers into the first successful mass production techniques. Nevertheless, the decision was made to develop a dried plasma package for the armed forces as it would reduce breakage and make the transportation, packaging, and storage much simpler. The resulting dried plasma package came in two tin cans containing 400 cc bottles. One bottle contained enough distilled water to reconstitute the dried plasma contained within the other bottle. In about three minutes, the plasma would be ready to use and could stay fresh for around four hours. The Blood for Britain program operated successfully for five months, with total collections of almost 15,000 people donating blood, and with over 5,500 vials of blood plasma. Following the Supplying Blood Plasma to England project, Drew was named director of the Red Cross blood bank and assistant director of the National Research Council, in charge of blood collection for the United States Army and Navy. Drew argued against the armed forces directive that blood/plasma was to be separated by the race of the donor.
Predominantly, the "energy expenditure hormone" leptin is made by adipose cells, and is thus labeled fat cell-specific. In the context of its effects, the adjectives central, direct, and primary are not used interchangeably. In regard to the hormone leptin, central vs peripheral refers to the hypothalamic portion of the brain vs non-hypothalamic location of action of leptin; direct vs indirect refers to whether there is no intermediary, or there is an intermediary in the mode of action of leptin; and primary vs secondary is an arbitrary description of a particular function of leptin.
Unresolved complex mixture (UCM), or hump, is a feature frequently observed in gas chromatographic (GC) data of crude oils and extracts from organisms exposed to oil. The reason for the UCM hump appearance is that GC cannot resolve and identify a significant part of the hydrocarbons in crude oils. The resolved components appear as peaks while the UCM appears as a large background/platform. In non-biodegraded oils the UCM may comprise less than 50% of the total area of the chromatogram, while in biodegraded oils this figure can rise to over 90%. UCMs are also observed in certain refined fractions such as lubricating oils and references therein. In attempting to determine "the processes that regulate the fate of petroleum following release to the environment,” geochemist Christopher M. Reddy of Woods Hole Oceanographic Institution invented an application of comprehensive two-dimensional gas chromatography (GCxGC) that resolves UMPs and that he patented. As it degrades in a marine environment, oil undergoes complex transformations, producing residues composed of extremely complex organic mixtures that accumulate in such “protective environments” as fiddler crabs and marsh grass. These residues form the majority of the unresolved complex mixture (UCM) resulting from the breakdown of crude oils that GC had previously been unable to resolve but which Reddy’s novel GCxGC application has made accessible, enabling determination of “the underlying processes controlling petroleum fate” as it degrades in a marine environment.
== Crystallization == The most stable lithium titanate phase is β-Li2TiO3 that belongs to the monoclinic system. A high-temperature cubic phase exhibiting solid-solution type behavior is referred to as γ-Li2TiO3 and is known to form reversibly above temperatures in the range 1150-1250 °C. A metastable cubic phase, isostructural with γ-Li2TiO3 is referred to as α-Li2TiO3; it is formed at low temperatures, and transforms to the more stable β-phase upon heating to 400 °C.
== Medical uses == Tazarotene is most commonly used topically to treat acne vulgaris, psoriasis, and photoaging. Like other topical retinoids, such as tretinoin and adapalene, tazarotene can be used in a regimen with benzoyl peroxide and/or an oral antibiotic, such as clindamycin or dapsone, for the treatment of acne. This results in increased efficacy compared to tazarotene monotherapy. Combination therapy utilizing tazarotene alongside a mid- to high-potency corticosteroid is more effective in treating psoriasis compared to monotherapy of either drug. Tazarotene can also be used for the treatment of photodamaged skin. It can reduce the histological and clinical signs of photodamaged skin, such as fine lines, wrinkles, hyperpigmentation, and lentigo. The therapy is more effective when used with the daily application of sunscreen.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
反相高效液相色谱用于分离和纯度评估，质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。